Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma

Monaldi Archives for Chest Disease

Volumn 51, Issue 4, 1996, Pages 275-278

  Bagnato, G F ^a,b   Mileto, A ^a   Gulli, S ^a   Oriti, S ^a   Di Cesare, E ^a   Cinquegrani, M ^a   Bonaiuto, M ^a   Saitta, A ^a   Purello D'Ambrosio, F ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Adverse effects; Beta2 adrenoceptor agonists; Bronchial asthma; Placebo; Salbutamol; Salmeterol

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; ASTHMA; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTRASYSTOLE; FEMALE; HEART RATE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PEAK EXPIRATORY FLOW; PR INTERVAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 16044374351     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Johnson M. - The pharmacology of salmeterol. Lung 1990; 168 (Suppl.): 115-119.
2. 2-adrenoceptor agonist: a comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
3. Ullman A, Hedner J, Svedmyr N. - Inhaled salmeterol and salbutamol in asthmatic patients. Am Rev Respir Dis 1990; 142: 571-575.
4. 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991; 104: 665-671.
5. 2-agonist. BMJ 1990; 301: 1365-1368.
6. Maconochie JG, Denyer LH, Lettis S. - Pharmacological effect of regular treatment with salmeterol in healthy subjects (Abstract). Am Rev Respir Dis 1992; 145 (4, part 2): A63.
7. Ratner PR, Findlay SR. - Electrocardiographic safety monitoring during salmeterol therapy of asthma (Abstract). Am Rev Respir Dis 1992; 145 (4, part 2): A65.
8. Dahl R, Earnshaw JS, Palmer JBD. - Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4: 1178-1184.
9. Sinclair BL, Clark DWJ, Sears MR. - Use of anti-asthma drugs in New Zealand. Thorax 1987; 42: 670-675.
10. Crane J, Pearce N, Platt A, et al. - Prescribed fenoterol and death rate from asthma in New Zealand, 1981-1983: case control study. Lancet 1989; i: 917-922.
11. Pearce N, Grainger J, Atkinson M, et al. - Casecontrol study of prescribed fenoterol and death from asthma in New Zealand, 1977-1981. Thorax 1990; 45: 170-175.
12. Scheinin M, Koulu M, Laurikainmen E, Allonen H. - Hypokalaemia and other nonbronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol 1987; 24: 645-653.
13. 2-agonist (Abstract). Am Rev Respir Dis 1989; 139: A64.
14. Kemp JP, Meltzer EO, Orgel HA, et al. - A comparative study of salmeterol, albuterol, and placebo via MDI in asthmatic adults (Abstract). J Allergy Clin Immunol 1989; 83: 186.
15. Pauwels R, Derom E. - Salmeterol's early development and challenge studies. Eur Respir Rev 1991; 1(4): 261-264.
16. Maconochie JG, Forster JK. - Dose-response study with high-dose inhaled SM in healthy subjects. Br J Clin Pharmacol 1992; 33: 342-345.
17. Minton NA, Kensington JE, Maconochie JG, Keene ON. - Does tachyphylaxis occur to the nonpulmonary effects of salmeterol? (Abstract). Br J Clin Pharmacol 1991; 31: 241-242.
18. Brogden N, Faults D. - Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42(5): 895-912.